Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis
- PMID: 20699106
- DOI: 10.1016/j.bbr.2010.08.001
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis
Abstract
Lack of appropriate animal models simulating core behavioural aspects of human psychosis is a major limitation in schizophrenia research. The use of drugs, that is believed to act through N-methyl d-aspartate receptor, has been demonstrated to mimic relatively broader range of behavioural symptoms in putative animal models. Our goal in this study has been to further evaluate one such drug, ketamine in mice and characterize some selective behavioural phenotypes associated with the drug dosage, treatment period and withdrawal effects to extend the understanding of this model. Our results indicate that acute treatment of ketamine (100 mg/kg, i.p.) induced hyperlocomotory response and reduced the 'transfer-latency time' in passive avoidance test but did not have any effect in the forced swim test (negative symptoms). In contrast, chronic administration of ketamine not only produced significant 'hyperactivity' response but also enhanced the immobility period in animals during the forced swim test and reduced the latency period in the passive avoidance test. Further, these behavioural alterations persisted at least for 10 days after the withdrawal of ketamine treatment. These observations were substantiated by using standard typical and atypical antipsychotic drugs, haloperidol (0.25 mg/kg, i.p.), clozapine (10 mg/kg, i.p.) and risperidone (0.025 mg/kg, i.p.). Therefore, the present study suggests that the chronic treatment with ketamine has the potential of exhibiting changes in broader range of behavioural domains than the acute treatment. Hence, animals chronically treated with ketamine might serve as a useful tool to study the underlying pathogenic mechanisms associated with some symptoms in schizophrenia and other psychiatric disorders.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):310-6. doi: 10.1016/j.pnpbp.2012.04.018. Epub 2012 Apr 26. Prog Neuropsychopharmacol Biol Psychiatry. 2012. PMID: 22561603
-
Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1267-77. doi: 10.1016/j.pnpbp.2004.06.019. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15588753
-
A putative animal model of the "prodromal" state of schizophrenia.Biol Psychiatry. 2005 Mar 15;57(6):586-93. doi: 10.1016/j.biopsych.2004.12.013. Biol Psychiatry. 2005. PMID: 15780845
-
Serotonin and dopamine interactions in psychosis prevention.Prog Brain Res. 2008;172:141-53. doi: 10.1016/S0079-6123(08)00907-2. Prog Brain Res. 2008. PMID: 18772031 Review.
-
Clozapine withdrawal resulting in delirium with psychosis: a report of three cases.J Clin Psychiatry. 1997 Jun;58(6):252-5. doi: 10.4088/jcp.v58n0603. J Clin Psychiatry. 1997. PMID: 9228890 Review.
Cited by
-
Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice.Neurochem Res. 2012 Apr;37(4):759-70. doi: 10.1007/s11064-011-0670-4. Epub 2011 Dec 22. Neurochem Res. 2012. PMID: 22189635
-
CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects.Cannabis Cannabinoid Res. 2023 Oct;8(5):768-778. doi: 10.1089/can.2022.0072. Epub 2022 Sep 2. Cannabis Cannabinoid Res. 2023. PMID: 36067014 Free PMC article.
-
C57BL/6N mice show a sub-strain specific resistance to the psychotomimetic effects of ketamine.Front Behav Neurosci. 2022 Nov 24;16:1057319. doi: 10.3389/fnbeh.2022.1057319. eCollection 2022. Front Behav Neurosci. 2022. PMID: 36505728 Free PMC article.
-
Ketamine's Effects on the Glutamatergic and GABAergic Systems: A Proteomics and Metabolomics Study in Mice.Mol Neuropsychiatry. 2019 Mar;5(1):42-51. doi: 10.1159/000493425. Epub 2018 Nov 15. Mol Neuropsychiatry. 2019. PMID: 31019917 Free PMC article.
-
Behavioral and electrophysiological effects of endocannabinoid and dopaminergic systems on salient stimuli.Front Behav Neurosci. 2014 May 19;8:183. doi: 10.3389/fnbeh.2014.00183. eCollection 2014. Front Behav Neurosci. 2014. PMID: 24904335 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
